As both these trials demonstrated an OS benefit over Clb alone, treatment with O-Clb, R-Clb or ibrutinib has become the cornerstone of first-line therapy in unfit CLL patients. The gene discussed is CLYBL; the disease is B-cell chronic lymphocytic leukemia.